Education
About Us
Working with TipRanks
Follow Us
Kalaris Therapeutics (KLRS)
NASDAQ:KLRS
KLRS Stock Chart & Stats
$9.08
--
Market closed
$9.08
--
Day’s Range― - ―
52-Week Range$2.14 - $12.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)136.22K
Market Cap
$151.98M
Enterprise Value$127.76M
Total Cash (Recent Filing)$77.00M
Total Debt (Recent Filing)$1.54M
Price to Earnings (P/E)―
Beta0.53
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.75
Shares Outstanding18,702,417
10 Day Avg. Volume189,046
30 Day Avg. Volume136,224
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.40
Price to Sales (P/S)0.00
P/FCF Ratio-0.67
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.99
Forecast
1Y Price Target
$16.67Price Target Upside83.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extended Runway From FinancingAn oversubscribed private placement expected to raise ~$50M materially extends runway into Q3 2027. This durable cash buffer gives management time to advance TH103 through clinical milestones, reducing immediate refinancing pressure and enabling strategic trial planning and partnerships.
Promising Phase 1a Clinical DataPositive single-injection Phase 1a results showing meaningful vision gains and tolerability support TH103’s extended-retention design. Clinically durable efficacy and safety enhance the candidate’s differentiation, improving prospects for later-stage development, payer interest, and potential partnering or licensing.
Strengthened Financial LeadershipHiring an experienced biotech CFO from iTeos/Sarepta strengthens capital markets credibility and execution capability. Durable benefit: improved capital planning, fundraising execution, and financial controls that are critical for a clinical-stage firm reliant on periodic financing to fund trials and manage dilution risk.
Bears Say
No Meaningful Revenue BaseKalaris remains a development-stage firm with negligible product revenue, meaning long-term viability hinges on successful clinical outcomes or partner deals. Without recurring revenue, the company lacks internal cash generation and is structurally dependent on external capital and milestone realization.
Accelerating Cash BurnA sharp increase in operating cash outflows in 2024 materially raises funding needs and dilution risk. Sustained high burn without revenue or near-term material milestones forces frequent capital raises, constraining strategic optionality and pressuring management to prioritize spend efficiency and milestone pacing.
Negative Returns On Equity; Funding DependenceAlthough equity was recapitalized, persistently negative ROE shows capital has yet to generate returns. Long-term value creation depends on converting R&D investment into clinical and commercial success; until then, reliance on equity financings risks dilution and limits shareholder return prospects.
Kalaris Therapeutics News
KLRS FAQ
What was Kalaris Therapeutics’s price range in the past 12 months?
Kalaris Therapeutics lowest stock price was $2.14 and its highest was $12.90 in the past 12 months.
What is Kalaris Therapeutics’s market cap?
Kalaris Therapeutics’s market cap is $151.98M.
When is Kalaris Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kalaris Therapeutics’s earnings last quarter?
Kalaris Therapeutics released its earnings results on Aug 13, 2025. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.46 by -$0.15.
Is Kalaris Therapeutics overvalued?
According to Wall Street analysts Kalaris Therapeutics’s price is currently Undervalued.
Does Kalaris Therapeutics pay dividends?
Kalaris Therapeutics does not currently pay dividends.
What is Kalaris Therapeutics’s EPS estimate?
Kalaris Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kalaris Therapeutics have?
Kalaris Therapeutics has 18,702,417 shares outstanding.
What happened to Kalaris Therapeutics’s price movement after its last earnings report?
Kalaris Therapeutics reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.46. Following the earnings report the stock price went down -2.17%.
Which hedge fund is a major shareholder of Kalaris Therapeutics?
Currently, no hedge funds are holding shares in KLRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kalaris Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.67 (83.59% Upside)
$16.67 (83.59% Upside)
Hedge Fund Trend
Decreased
By 141.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.99%
12-Months-Change
Fundamentals
Return on Equity
-63.45%
Trailing 12-Months
Asset Growth
-33.75%
Trailing 12-Months
Company Description
Kalaris Therapeutics
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
KLRS Stock 12 Month Forecast
Average Price Target
$16.67
▲(83.59% Upside)
Technical Analysis
Coherus Biosciences
―
Nektar Therapeutics
―
Cellectis SA
―
Seres Therapeutics
―
Kodiak Sciences
―